Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Influence of Assay Error Weight on Gentamicin Pharmacokinetics Using the Bayesian and Nonlinear Least Square Regression Analysis in Appendicitis Patients

  • Published : 2005.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to determine the influence of weight with gentamicin assay error on the Bayesian and nonlinear least squares regression analysis in 12 Korean appen dicitis patients. Gentamicin was administered intravenously over 0.5 h every 8 h. Three specimens were collected at 48 h after the first dose from all patients at the following times, just before regularly scheduled infusion, at 0.5 h and 2 h after the end of 0.5 h infusion. Serum gentamicin levels were analyzed by fluorescence polarization immunoassay technique with TDxFLx. The standard deviation (SD) of the assay over its working range had been determined at the serum gentamicin concentrations of 0, 2, 4, 8, 12, and 16 ${\mu}g$/mL in quadruplicate. The polynominal equation of gentamicin assay error was found to be SD (${\mu}g$/mL) = 0.0246-(0.0495C)+ (0.00203C$^2$). There were differences in the influence of weight with gentamicin assay error on pharmacokinetic parameters of gentamicin using the nonlinear least squares regression analysis but there were no differences on the Bayesian analysis. This polynominal equation can be used to improve the precision of fitting of pharmacokinetic models to optimize the process of model simulation both for population and for individualized pharmacokinetic models. The result would be improved dosage regimens and better, safer care of patients receiving gentamicin.

Keywords

References

  1. Bisno, A. L., Dismukes, W. E., and Durack, D. T., Antimicrobial treatment of infective endocarditis due to viridans streptococci, and staphylococci. JAMA, 261, 1471-1477 (1987) https://doi.org/10.1001/jama.261.10.1471
  2. Burm, J. P., Choi, J. S., Jhee, S., and Gill, M. A., Population pharmacokinetics for gentamicin in American and Korean- American appendicitis patients using Nonparametric expected maximum algorithm. Yakhak Hoeji, 39, 103-112 (1995)
  3. Choi, J. S., Moon, H. S., Choi, I., and Burm, J. P., Clinical pharmacokinetics of gentamicin in gastrointestnal surgical patients. Yakhak Hoeji, 40, 1-9 (1996)
  4. Chrystn, H., Validation of the use of Bayesian analysis in the optimization of gentamicin therpy from the commencement of dosing. Drug Intell. Clin. Pharm., 22, 49-53 (1988) https://doi.org/10.1177/106002808802200112
  5. Dahlgren, J. G., Anderson, E. T., and Hewitt, W. L., Gentamicin blood level: A guide to nephrotoxicity. Antimicrob. Agents Chemother., 8, 58-62 (1975) https://doi.org/10.1128/AAC.8.1.58
  6. DeGroot, M. H., Probability and statistics. Reading, Mass., Addison-Wesley Company, 357-360. (1975)
  7. Federspil, P., Ototoxicity of tobramycin and other aminoglycosides. Nouv. Presse. Med., 29, 3846-3848 (1978)
  8. Garrison, M. W., Zaske, D. E., and Rotschafer, J. C., Aminoglycosides: another perspective, DICP. Ann. Pharmacother., 24, 267-272 (1990)
  9. Jelliffe, R. W. and Schumitzky, A., User manual for the nonparametric EM program for population pharmacokinetic modeling version 1. University of Southern California School of Medicine, Los Angeles, Calfornia. (1988a)
  10. Jelliffe, R. W., D'Argenio, D. Z., Schumitzky, A., Hu, L., and Liu, M., The USC$\star$PACK PC programs for planning, monitoring and adjusting drug dosage regimens. Proceedings of the twenty-third annual meeting of the Association for the Advancement of Medical Instrumentation. Washington, DC, May, 13-18 (1988b)
  11. Jelliffe, R. W., Iglesias, T., Hurst, A. K., Foo, K. A., and Rodriguez, J., Individualizing drug dosage regimens: Comparision of two types of pharmacokinetic models of gentamicin, three methods of fitting serum level data, and several strategies. USC Laboratory of Applied Pharmacikinetics Technical Report, Report No. 88-1 (1988c)
  12. Jelliffe, R. W., Iglesias, T., and Hurst, A. K., Individualizing gentamicin dosage regimens. A comparative review of selected methods. Data fitting methods and monitoring strategies. Clin. Pharmacokinet., 21, 471-478(1991)
  13. Moore, R. D., Smith, C. R., and Lietman, P. S., The association of aminoglycoside plasma levels with mortality in patients with gram negative bacteremia. J. Infect. Dis., 149, 43-48 (1984) https://doi.org/10.1093/infdis/149.3.443
  14. Noone, P., Parson, T. N. C., and Pattison, J. R., Experiance in monitoring gentamicin therapy during treatment of serious gram negative sepsis. Br. Med. J., 1, 477-481 (1974) https://doi.org/10.1136/bmj.1.5906.477
  15. Powell, S. H., Thompson, W. L., and Luthie, M. A., Once daily versus continuous aminoglycoside dosing. Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J. Infect. Dis., 147, 918-932 (1983) https://doi.org/10.1093/infdis/147.5.918
  16. Sawchuk, R. J. and Zaske, D. E., Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients. J. Pharmacokinet. Biopharm., 4, 183-195 (1976) https://doi.org/10.1007/BF01086153
  17. Schumacher, G. E. and Barr, J. T., Bayesian approaches in pharmacokinetic decision making. Clin. Pharm., 3, 525-530 (1984)
  18. Sheiner, L. B., Beal, S. L., Rosenberg, B., and Marathe, B., Forecasting individual pharmacokinetics. Clin. Pharmacol. Ther., 26, 294-325 (1979) https://doi.org/10.1002/cpt1979263294
  19. Sheiner, L. B. and Beal, S. L., Bayesian individualization of pharmacokinetics. Simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci. 1, 1344-1348 (1982) https://doi.org/10.1002/jps.2600711209
  20. Stevens, M. R., Computerized pharmacokinetic in therpeutic drug monitoring. ASCP Clinical Pharmacology Check Sample No. CP 86-5 (CP-41), Chicago, Am. Soc. Clin. Patho. (1987)
  21. Zaske, D. and Cipolle, R., Amonoglyciside dosing program, 2nd ed, St. Paul-Ramsey Hospital, St. Paul, Minn. (1983)